nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

01.10.2013 | Editorial

SUV_max of 2.5 should not be embraced as a magic threshold for separating benign from malignant lesions

verfasst von: Thomas C. Kwee, Gang Cheng, Marnix G. E. H. Lam, Sandip Basu, Abass Alavi

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 10/2013

Einloggen, um Zugang zu erhalten

Excerpt

Lesions of an indeterminate nature are often encountered in images such as those from CT and MRI. Examples include solitary pulmonary nodules and various incidentalomas that may be found in any body region. FDG PET can be useful in differentiating benign from malignant lesions, given the fact that malignant lesions generally have a higher glycolytic rate and consequently higher FDG uptake. Both visual image interpretation and (semiquantitative) standardized uptake value (SUV) measurements may be used for this purpose. Some clinicians advocate the use of a maximum SUV (SUV_max) threshold of 2.5 to separate benign from malignant lesions, which is based on the results of several old studies that were published more than 10 years ago [1, 2]. However, this approach suffers from major shortcomings, which may lead to patient mismanagement. This communication aims to clarify several important issues on the validity of using an SUV_max threshold of 2.5 to differentiate benign from malignant lesions. …

Hain SF, Curran KM, Beggs AD, Fogelman I, O’Doherty MJ, Maisey MN. FDG-PET as a “metabolic biopsy” tool in thoracic lesions with indeterminate biopsy. Eur J Nucl Med. 2001;28:1336–40.PubMedCrossRef

Beggs AD, Hain SF, Curran KM, O’Doherty MJ. FDG-PET as a “metabolic biopsy” tool in non-lung lesions with indeterminate biopsy. Eur J Nucl Med Mol Imaging. 2002;29:542–6.PubMedCrossRef

Thie JA. Understanding the standardized uptake value, its methods, and implications for usage. J Nucl Med. 2004;45:1431–4.PubMed

Graham MM, Badawi RD, Wahl RL. Variations in PET/CT methodology for oncologic imaging at U.S. academic medical centers: an imaging response assessment team survey. J Nucl Med. 2011;52:311–7.PubMedCrossRef

Boellaard R, O’Doherty MJ, Weber WA, Mottaghy FM, Lonsdale MN, Stroobants SG, et al. FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging. 2010;37:181–200.PubMedCrossRef

Basu S, Alavi A. Partial volume correction of standardized uptake values and the dual time point in FDG-PET imaging: should these be routinely employed in assessing patients with cancer? Eur J Nucl Med Mol Imaging. 2007;34:1527–9.PubMedCrossRef

Basu S, Kwee TC, Torigian D, Saboury B, Alavi A. Suboptimal and inadequate quantification: an alarming crisis in medical applications of PET. Eur J Nucl Med Mol Imaging. 2011;38:1381–2.PubMedCrossRef

Hickeson M, Yun M, Matthies A, Zhuang H, Adam LE, Lacorte L, et al. Use of a corrected standardized uptake value based on the lesion size on CT permits accurate characterization of lung nodules on FDG-PET. Eur J Nucl Med Mol Imaging. 2002;29:1639–47.PubMedCrossRef

Soret M, Bacharach SL, Buvat I. Partial-volume effect in PET tumor imaging. J Nucl Med. 2007;48:932–45.PubMedCrossRef

10.

Hoetjes NJ, van Velden FH, Hoekstra OS, Hoekstra CJ, Krak NC, Lammertsma AA, et al. Partial volume correction strategies for quantitative FDG PET in oncology. Eur J Nucl Med Mol Imaging. 2010;37:1679–87.PubMedCrossRef

11.

Basu S, Saboury B, Torigian DA, Alavi A. Current evidence base of FDG-PET/CT imaging in the clinical management of malignant pleural mesothelioma: emerging significance of image segmentation and global disease assessment. Mol Imaging Biol. 2011;13:801–11.PubMedCrossRef

12.

Musiek ES, Saboury B, Mishra S, Chen Y, Reddin JS, Newberg AB, et al. Feasibility of estimation of brain volume and 2-deoxy-2-(18)F-fluoro-D-glucose metabolism using a novel automated image analysis method: application in Alzheimer’s disease. Hell J Nucl Med. 2012;15:190–6.PubMed

13.

Cheng G, Alavi A, Lim E, Werner TJ, Del Bello CV, Akers SR. Dynamic changes of FDG uptake and clearance in normal tissues. Mol Imaging Biol. 2013;15:345–52.PubMedCrossRef

14.

Cheng G, Torigian DA, Zhuang H, Alavi A. When should we recommend use of dual time-point and delayed time-point imaging techniques in FDG PET? Eur J Nucl Med Mol Imaging. 2013;40:779–87.PubMedCrossRef

15.

Sathekge MM, Maes A, Pottel H, Stoltz A, van de Wiele C. Dual time-point FDG PET-CT for differentiating benign from malignant solitary pulmonary nodules in a TB endemic area. S Afr Med J. 2010;100:598–601.PubMed

16.

Shreve PD, Anzai Y, Wahl RL. Pitfalls in oncologic diagnosis with FDG PET imaging: physiologic and benign variants. Radiographics. 1999;19:61–77.PubMed

17.

Kwee TC, Basu S, Saboury B, Ambrosini V, Torigian DA, Alavi A. A new dimension of FDG-PET interpretation: assessment of tumor biology. Eur J Nucl Med Mol Imaging. 2011;38:1158–70.PubMedCrossRef

Titel: SUVmax of 2.5 should not be embraced as a magic threshold for separating benign from malignant lesions
verfasst von: Thomas C. Kwee
Gang Cheng
Marnix G. E. H. Lam
Sandip Basu
Abass Alavi
Publikationsdatum: 01.10.2013
Verlag: Springer Berlin Heidelberg
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 10/2013
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-013-2484-x

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 10/2013

Observer reproducibility of results from a low-dose 123I-metaiodobenzylguanidine cardiac imaging protocol in patients with heart failure

PET/MRI with a 68Ga-PSMA ligand for the detection of prostate cancer

[11C]PIB, [18F]FDG and MR imaging in patients with mild cognitive impairment

Giuliano Mariani, Gianpiero Manca, Federica Orsini, Sergi Vidal-Sicart, Renato A. Valdés Olmos (eds): Atlas of Lymphoscintigraphy and Sentinel Node Mapping

In vivo bioluminescence reporter gene imaging for the activation of neuronal differentiation induced by the neuronal activator neurogenin 1 (Ngn1) in neuronal precursor cells

H. William Strauss, Giuliano Mariani, Duccio Volterrani, Steven M. Larson (eds): Nuclear Oncology: Pathophysiology and Clinical Applications